US10667730B2ExpiredUtilityA1

Analyte sensing biointerface

Assignee: DEXCOM INCPriority: Apr 15, 2005Filed: Oct 16, 2019Granted: Jun 2, 2020
Est. expiryApr 15, 2025(expired)· nominal 20-yr term from priority
A61B 5/14532A61B 5/14865A61B 5/0031A61B 5/1486C12Q 1/001B33Y 80/00C12Q 1/006
70
PatentIndex Score
0
Cited by
668
References
9
Claims

Abstract

Disclosed herein is an analyte sensing biointerface that comprises a sensing electrode incorporated within a non-conductive matrix comprising a plurality of passageways extending through the matrix to the sensing electrode. Also disclosed herein are methods of manufacturing a sensing biointerface and methods of detecting an analyte within tissue of a host using an analyte sensing biointerface.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A transcutaneous continuous glucose sensor system, comprising:
 a substantially planar sensor, the sensor comprising:
 a first non-conductive layer; 
 a first conductive layer associated with a first electrode, wherein the first conductive layer is disposed over at least a portion of the first non-conductive layer, wherein the first electrode is a counter electrode; 
 a second non-conductive layer disposed over at least a portion of the first conductive layer; 
 a second conductive layer associated with a second electrode, wherein the second conductive layer is disposed over at least a portion of the second non-conductive layer, wherein the second electrode is a working electrode; 
 a third non-conductive layer disposed over at least a portion of the second conductive layer; 
 a third conductive layer associated with a third electrode, wherein the third conductive layer is disposed over at least a portion of the third non-conductive layer, wherein the third electrode is a reference electrode; and 
 a membrane disposed over at least a portion of the working electrode. 
 
 
     
     
       2. The transcutaneous continuous glucose sensor system of  claim 1 , wherein the membrane comprises an enzyme. 
     
     
       3. The transcutaneous continuous glucose sensor system of  claim 2 , wherein the membrane further comprises a resistance domain disposed over the enzyme. 
     
     
       4. The transcutaneous continuous glucose sensor system of  claim 1 , wherein the membrane further comprises a bioactive agent. 
     
     
       5. The transcutaneous continuous glucose sensor system of  claim 1 , wherein the membrane is substantially planar. 
     
     
       6. The transcutaneous continuous glucose sensor system of  claim 1 , wherein at least a portion of the first non-conductive layer is in contact with at least a portion of the first conductive layer. 
     
     
       7. The transcutaneous continuous glucose sensor system of  claim 1 , further comprising sensor electronics configured to electrically couple to the working electrode. 
     
     
       8. The transcutaneous continuous glucose sensor system of  claim 1 , wherein at least a portion of the first non-conductive layer is physically separate from the first conductive layer. 
     
     
       9. The transcutaneous continuous glucose sensor system of  claim 1 , further comprising sensor electronics comprising at least one contact for establishing electrical communication with the working electrode.

Join the waitlist — get patent alerts

Track US10667730B2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.